Hikma Pharmaceuticals PLC HIK shares shed 3.16% to £19.02 Friday, on what proved to be an all-around rough trading session ...

Shares of Hikma Pharmaceuticals PLC HIK dropped 1.95% to £19.15 Tuesday, on what proved to be an all-around favorable trading ...

IBD is a chronic inflammation of the intestine characterised by severe stomach pain and diarrhoea affecting nearly 5 million people worldwide Riyadh – Hikma Pharmaceuticals KSA, announced the ...

Hikma has completed its acquisition of Xellia Pharmaceuticals’ U.S. finished dosage form business and related assets following clearance under applicable U.S. antitrust laws. The acquisition ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

(RTTNews) - Zentalis Pharmaceuticals (ZNTL) announced the FDA has lifted the partial clinical hold on studies of azenosertib, the company's selective, and orally bioavailable inhibitor of WEE.

(RTTNews) - Vanda Pharmaceuticals (VNDA) said, on September 18, the FDA declined to approve New Drug Application of tradipitant for the treatment of symptoms in gastroparesis, providing the ...

Barclays cuts Prudential price target to 1,250 (1,380) pence - 'overweight' Barclays reinitiates Barratt Developments with 'overweight' - price target 641 pence Barclays raises HGCapital Trust to ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

VICTORIA, BC, Sept. 19, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...